EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Access to innovative therapies in pediatric oncology: Report of the nationwide experience in Canada

Sandra Judd, Gabriel Revon-Riviere iD, Stephanie A Grover, Rebecca J Deyell iD, Magimairajan Issai Vanan iD, Victor A Lewis, Lucie Pecheux, Alexandra P Zorzi, Catherine Goudie, Raoul Santiago, Thai Hoa Tran, Lesleigh S Abbott und 8 weitere

Cancer Medicine · 2024

DOI: 10.1002/cam4.7033 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Sandra Judd und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Hospital for Sick Children, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The need for new therapies to improve survival and outcomes in pediatric oncology along with the lack of approval and accessible clinical trials has led to “out‐of‐trial” use of innovative therapies. We conducted a retrospective analysis of requests for innovative anticancer therapy in Canadian pediatric oncology tertiary centers for patients less than 30 years old between 2013 and 2020.

Methods

Innovative therapies were defined as cancer‐directed drugs used (a) off‐label, (b) unlicensed drugs being used outside the context of a clinical trial, or (c) approved drugs with limited evidence in pediatrics. We excluded cytotoxic chemotherapy, cellular products, and cytokines.

Results

We retrieved data on 352 innovative therapy drug requests. Underlying diagnosis was primary CNS tumor 31%; extracranial solid tumor 37%, leukemia/lymphoma 22%, LCH 2%, and plexiform neurofibroma 6%. RAS/MAP kinase pathway inhibitors were the most frequently requested innovative therapies in 28% of all requests followed by multi‐targeted tyrosine kinase inhibitors (17%), inhibitors of the PIK3CA‐mTOR‐AKT pathway (8%), immune checkpoints inhibitors (8%), and antibody drug conjugates (8%). In 112 out of 352 requests, innovative therapies were used in combination with another anticancer agent. 48% of requests were motivated by the presence of an actionable molecular target. Compassionate access accounted for 52% of all requests while public insurance was used in 27%. Mechanisms of funding varied between provinces.

Conclusion

This real‐world data collection illustrates an increasing use of “out‐of‐trial” innovative therapies in pediatric oncology. This new field of practice warrants further studies to understand the impact on patient trajectory and equity in access to innovative therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAntineoplastic AgentsHumansChildAdultRetrospective StudiesCanadaMedical OncologyTherapies, Investigational

Stichwörter der Autor:innen

immunotherapyprecision oncologyreal-world datatargeted therapy

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Pharmacy, Hospital for Sick Children, Toronto, Ontario, Canada.
  • Division of Haematology/Oncology, Hospital for Sick Children, Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada.
  • Genetics and Genome Biology, Hospital for Sick Children, Toronto, Ontario, Canada.
  • Division of Pediatric Hematology Oncology BMT, BC Children's Hospital and Research Institute, Vancouver, British Columbia, Canada.
  • Pediatric Neuro-Oncology, Division of Pediatric Hematology-Oncology, Cancer Care Manitoba, University of Manitoba, Winnipeg, Manitoba, Canada.
  • University of Calgary, Alberta, Canada.

ORCID-Profile: Gabriel Revon-Riviere, Rebecca J Deyell, Magimairajan Issai Vanan, Avram Denburg, James A Whitlock, Sarah Cohen-Gogo, Daniel A Morgenstern

Zitieren

APA

Judd, S., Revon-Riviere, G., Grover, S. A., Deyell, R. J., Vanan, M. I., Lewis, V. A., Pecheux, L., Zorzi, A. P., Goudie, C., Santiago, R., Tran, T. H., Abbott, L. S., Brossard, J., Moorehead, P., Alvi, S., Portwine, C., Denburg, A., Whitlock, J. A., Cohen-Gogo, S., & Morgenstern, D. A. (2024). Access to innovative therapies in pediatric oncology: Report of the nationwide experience in Canada. Cancer Medicine. https://doi.org/10.1002/cam4.7033

Vancouver

Judd S, Revon-Riviere G, Grover SA, Deyell RJ, Vanan MI, Lewis VA, et al. Access to innovative therapies in pediatric oncology: Report of the nationwide experience in Canada. Cancer Medicine. 2024. doi:10.1002/cam4.7033

BibTeX
@article{Judd2024,
  author = {Judd, Sandra and Revon-Riviere, Gabriel and Grover, Stephanie A and Deyell, Rebecca J and Vanan, Magimairajan Issai and Lewis, Victor A and Pecheux, Lucie and Zorzi, Alexandra P and Goudie, Catherine and Santiago, Raoul and Tran, Thai Hoa and Abbott, Lesleigh S and Brossard, Josee and Moorehead, Paul and Alvi, Saima and Portwine, Carol and Denburg, Avram and Whitlock, James A and Cohen-Gogo, Sarah and Morgenstern, Daniel A},
  title = {Access to innovative therapies in pediatric oncology: Report of the nationwide experience in Canada},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.7033}
}
Kostenlos starten →